ILSI-Biomed Israel

Abbott Diagnostics @ Biomed 2011

Abbott Diagnostics will be attending Biomed 2011 and is interested in discussions with potential collaborators leading toward the development and commercialization of novel IA/CC biomarkers in all therapeutic areas: o Evidence of clinical utility o Well characterized antibody development o Preferably, a developed ELISA format o Workable, defendable, global IP position Tweet

BrainStorm Raises $3.6 M To Launch Phase I/II Trial for ALS.

The recent appointment of Adrian Harel as the CEO of BrainStorm Cell Therapeutics (OTCBB: BCLI) signals the beginning of a new era both for the company and for its new top exec. BrainStorm, after several hurdle-crossing years of pre-clinical testing and validation of its autologous stem cell therapy, is about to become the first Israeli company to reach the clinical trial stage with a differentiated stem cell-based therapy. The company`s Phase I/II trial, expected to begin in the spring,...

Vaxil’s TB vaccine successfully passes first stage in animal studies

Nes-Ziona, 8th March, 2011. Vaxil Biotherapeutics Ltd., a clinical stage developer of innovative therapeutic vaccines announced today that MTbuVax, its vaccine against the lethal bacteria Mycobacterium Tuberculosis (MTb) has proven to manifest effective induction of immune response in mice. The studies demonstrated that mice vaccinated with MTbuVax produced potent CD4+ and CD8+ T-cell immunity that specifically proliferated in response to the MTbuVax vaccine. In addition, T-cells from vac...

A film which explains about a new therapeutic vaccine for cancer – amazing!

Here is the film which explains about ImMucin, a new therapeutic vaccine for cancer which is currently in clinical trials in Myeloma patients. You are also invited to visit Vaxil BioTherapeutics site. Tweet

Foamix Announces Phase II Clinical Trial of Topical Minocycline Foam for Rosacea

The first-in-class topical Minocycline product, protected by 4 patent applications, is directed for the treatment of Rosacea, Acne, Skin Infections and Chronic Wounds. Foamix Ltd., a clinical-stage specialty pharmaceutical company focused on the development of proprietary dermatological and gynecologic topical products, today announced enrollment of the first patient in a Phase II trial of its Topical Minocycline Foam. The double-blind, placebo controlled dose range finding study aims to ...

Brainsway reports improvements in Australian autism trial

Brainsway Ltd. (TASE:BRIN) reports that interim results of an Australian study showed small but significant improvement in patients with autism or Asperger's syndrome treated with its Deep TMS (transcranial magnetic stimulation) device. The study showed improvement in the Theory of Mind (a designated coil for treating autism) and in social communications. The study conducted at the Monash Alfred Psychiatry Research Centre in Melbourne included 16 healthy adults and 20 patients with autis...

FDAnews Virtual Conference: Complying with FDA’s Unique Device Identification Rule; Feb 24 2011

The soon-to-be-issued FDA proposed rule requiring adoption of Unique Device Identification (UDI) has device manufacturers in a sweat. But an upcoming virtual conference for medical device companies promises to shed light. The FDA is about to unveil a proposed rule that could dramatically increase the volume and type of information you supply to the FDA. The new rule will require you to create a unique ID and label for every product that carries risk. The label will include name of manu...

Job Offer: Medical Director- Neuroscience; Boston

Description Key responsibilities for the Medical Director include: Accountability for the strategic planning and execution (including study design, method selection, etc) of Phase I through IV global clinical trials Analyze and interpret data expertly, and clearly communicate results both internally and externally. Assisting with medical evaluation of new proprietary opportunities and in-licensing activities Contributing to, reviewing, and approving clinical regulatory documents (clini...

BioCancell Announces Success in Pre-Clinical Trial of New Therapy BC-821 on Glioblastoma

BioCancell Therapeutics, Inc. has successfully completed pre-clinical animal studies, using mice, that examined the use of BioCancell's new product candidate BC-821 as a treatment for glioblastoma (the most common and agressive type of primary human brain tumor). The research, carried out by Dr. Doron Amit in the Hebrew University laboratory of Prof. Abraham Hochberg, BioCancell's founder and chief scientist, showed that BC-821 succeeded in significantly inhibiting brain tumor volume growth in a...

New Research From Israel: Aposesne

In a special Jewish Week feature, three Israeli cutting edge research projects are being introduced. One of them is Aposesne, an Israeli pharmaceutical company that is targeting a process that is integral to nearly every illness — apoptosis, or cellular death. Photo credit: ardelfin from morguefile.com “Apoptosis is associated with almost every medical disorder,” said Yoram Ashery, CEO of Aposense, a clinical stage molecular imaging and drug development company that completed its Initial P...